Sell Sprint!: Again...
Health Care: Drugs
Hana Biosciences Inc. (HNAB: OTC)
$0.56 -0.02 | -4.27%
12/01/10 - 03:54 PM ET
17.97K / 57.30K
Vol / Avg. Vol:0.56 / 0.58
Open / Prev. Close:0.56 - 0.57
Today's Range:0.30 - 2.56
52 Wk Range:-26.32%
Performance YTD:TheStreet Rating:
Portfolios with HNAB
- Portfolio NameUser Type
- Usergrainey Portfolio 1
- Usermhaynes Portfolio 1
- Userjeslau Portfolio 1
- UserMonitor Growth 07
- UserPANTERA GROUP 128
- UserSUPRATRADE SBSFXB-BIOSCIENC...
- Usercoryent Portfolio 1
- UserSED Portfolio 1
- UserPANTERA GROUP 44
- Usercdrydie Portfolio 1
Latest HNAB Headlines from TheStreet
- Hana Biosciences To Change Name To Talon Therapeutics 12.01.10 | 08:12 am
- Hana Biosciences To Present Data On Marqibo(R) At The 2010 American Society Of Hematology Annual Meeting And Exposition 11.29.10 | 09:11 am
- Hana Biosciences Reports Third Quarter 2010 Financial Results 11.12.10 | 09:11 am
- Hana Biosciences To Host A Conference Call To Report Third Quarter 2010 Results And Business Update On November 12, 2010 11.08.10 | 05:11 pm
- Hana Biosciences Reverse Stock Split Effective Monday, September 13, 2010 09.10.10 | 04:09 pm
- Hana Biosciences Reports Second Quarter 2010 Financial Results 08.13.10 | 06:08 am
- Hana Biosciences Appoints Robert Spiegel, M.D., FACP, To Board Of Directors 08.05.10 | 08:08 am
- Hana Biosciences Patent Issued For Menadione For The Prevention And Treatment Of EGFR Inhibitor Cancer Therapy-Associated Rash 07.08.10 | 08:07 am
- Hana Biosciences Announces Financing Of Up To $100 Million 06.07.10 | 10:06 am
- Data From Pivotal Phase 2 RALLY Trial Show Marqibo Produced Compelling Single-Agent Anti-Leukemic Efficacy In Advanced Relapsed/Refractory Adult Ph(-) Acute Lymphoblastic Leukemia 06.07.10 | 07:06 am
Press Releases for HNAB
Partner Headlines for HNAB
- Hana Bioscience: Poised To Deliver Shareholder Value - Analyst Blog - Zacks 11.09.10 | 07:11 am
